Literature DB >> 27895162

Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites.

Lawrence C Blume1, Theresa Patten1, Khalil Eldeeb1, Sandra Leone-Kabler1, Alexander A Ilyasov1, Bradley M Keegan1, Jeremy E O'Neal1, Caroline E Bass1, Roy R Hantgan1, W Todd Lowther1, Dana E Selley1, A Llyn C Howlett2.   

Abstract

Cannabinoid receptor interacting protein 1a (CRIP1a) is a CB1 receptor (CB1R) distal C-terminal-associated protein that alters CB1R interactions with G-proteins. We tested the hypothesis that CRIP1a is capable of also altering CB1R interactions with β-arrestin proteins that interact with the CB1R at the C-terminus. Coimmunoprecipitation studies indicated that CB1R associates in complexes with either CRIP1a or β-arrestin, but CRIP1a and β-arrestin fail to coimmunoprecipitate with each other. This suggests a competition for CRIP1a and β-arrestin binding to the CB1R, which we hypothesized could attenuate the action of β-arrestin to mediate CB1R internalization. We determined that agonist-mediated reduction of the density of cell surface endogenously expressed CB1Rs was clathrin and dynamin dependent and could be modeled as agonist-induced aggregation of transiently expressed GFP-CB1R. CRIP1a overexpression attenuated CP55940-mediated GFP-CB1R as well as endogenous β-arrestin redistribution to punctae, and conversely, CRIP1a knockdown augmented β-arrestin redistribution to punctae. Peptides mimicking the CB1R C-terminus could bind to both CRIP1a in cell extracts as well as purified recombinant CRIP1a. Affinity pull-down studies revealed that phosphorylation at threonine-468 of a CB1R distal C-terminus 14-mer peptide reduced CB1R-CRIP1a association. Coimmunoprecipitation of CB1R protein complexes demonstrated that central or distal C-terminal peptides competed for the CB1R association with CRIP1a, but that a phosphorylated central C-terminal peptide competed for association with β-arrestin 1, and phosphorylated central or distal C-terminal peptides competed for association with β-arrestin 2. Thus, CRIP1a can compete with β-arrestins for interaction with C-terminal CB1R domains that could affect agonist-driven, β-arrestin-mediated internalization of the CB1R.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27895162      PMCID: PMC5267523          DOI: 10.1124/mol.116.104638

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  65 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  Entropy drives integrin alphaIIbbeta3:echistatin binding--evidence from surface plasmon resonance spectroscopy.

Authors:  Roy R Hantgan; Mary C Stahle; David A Horita
Journal:  Biochemistry       Date:  2008-02-01       Impact factor: 3.162

Review 3.  Surface plasmon resonance biosensing.

Authors:  Marek Piliarik; Hana Vaisocherová; Jirí Homola
Journal:  Methods Mol Biol       Date:  2009

4.  Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis.

Authors:  Tom Kirchhausen; Eric Macia; Henry E Pelish
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

5.  Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.

Authors:  Evangelia Kotsikorou; Karla E Madrigal; Dow P Hurst; Haleli Sharir; Diane L Lynch; Susanne Heynen-Genel; Loribelle B Milan; Thomas D Y Chung; Herbert H Seltzman; Yushi Bai; Marc G Caron; Larry Barak; Mary E Abood; Patricia H Reggio
Journal:  Biochemistry       Date:  2011-06-01       Impact factor: 3.162

6.  Differential β-arrestin2 requirements for constitutive and agonist-induced internalization of the CB1 cannabinoid receptor.

Authors:  Pál Gyombolai; Eszter Boros; László Hunyady; Gábor Turu
Journal:  Mol Cell Endocrinol       Date:  2013-03-27       Impact factor: 4.102

7.  Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.

Authors:  Anikó Ludányi; Loránd Eross; Sándor Czirják; János Vajda; Péter Halász; Masahiko Watanabe; Miklós Palkovits; Zsófia Maglóczky; Tamás F Freund; István Katona
Journal:  J Neurosci       Date:  2008-03-19       Impact factor: 6.167

8.  Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace.

Authors:  Thomas J Jönsson; Lynnette C Johnson; W Todd Lowther
Journal:  Nature       Date:  2008-01-03       Impact factor: 49.962

9.  Generation and functional characterization of fluorescent, N-terminally tagged CB1 receptor chimeras for live-cell imaging.

Authors:  Neil A McDonald; Christopher M Henstridge; Christopher N Connolly; Andrew J Irving
Journal:  Mol Cell Neurosci       Date:  2007-03-03       Impact factor: 4.314

10.  Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation.

Authors:  Tricia H Smith; Lawrence C Blume; Alex Straiker; Jordan O Cox; Bethany G David; Julie R Secor McVoy; Katherine W Sayers; Justin L Poklis; Rehab A Abdullah; Michaela Egertová; Ching-Kang Chen; Ken Mackie; Maurice R Elphick; Allyn C Howlett; Dana E Selley
Journal:  Mol Pharmacol       Date:  2015-02-05       Impact factor: 4.436

View more
  18 in total

1.  Molecular Interaction between Distal C-Terminal Domain of the CB1 Cannabinoid Receptor and Cannabinoid Receptor Interacting Proteins (CRIP1a/CRIP1b).

Authors:  Pratishtha Singh; Anjali Ganjiwale; Allyn C Howlett; Sudha M Cowsik
Journal:  J Chem Inf Model       Date:  2019-12-10       Impact factor: 4.956

2.  In silico interaction analysis of cannabinoid receptor interacting protein 1b (CRIP1b) - CB1 cannabinoid receptor.

Authors:  Pratishtha Singh; Anjali Ganjiwale; Allyn C Howlett; Sudha M Cowsik
Journal:  J Mol Graph Model       Date:  2017-09-06       Impact factor: 2.518

Review 3.  G protein-coupled receptors in acquired epilepsy: Druggability and translatability.

Authors:  Ying Yu; Davis T Nguyen; Jianxiong Jiang
Journal:  Prog Neurobiol       Date:  2019-08-24       Impact factor: 11.685

4.  Developing Photoaffinity Probes for Dopamine Receptor D2 to Determine Targets of Parkinson's Disease Drugs.

Authors:  Spencer T Kim; Emma J Doukmak; Raymond G Flax; Dylan J Gray; Victoria N Zirimu; Ebbing de Jong; Rachel C Steinhardt
Journal:  ACS Chem Neurosci       Date:  2022-10-02       Impact factor: 5.780

5.  CB1 cannabinoid receptor-phosphorylated fourth intracellular loop structure-function relationships.

Authors:  Khalil Eldeeb; Anjali D Ganjiwale; Indu R Chandrashekaran; Lea W Padgett; Jason Burgess; Allyn C Howlett; Sudha M Cowsik
Journal:  Pept Sci (Hoboken)       Date:  2018-12-14

Review 6.  Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.

Authors:  Dai Lu; Sri Sujana Immadi; Zhixing Wu; Debra A Kendall
Journal:  Acta Pharmacol Sin       Date:  2018-10-17       Impact factor: 6.150

Review 7.  Review of the Endocannabinoid System.

Authors:  Hui-Chen Lu; Ken Mackie
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-08-01

8.  The Cannabinoid Receptor Interacting Proteins 1 of zebrafish are not required for morphological development, viability or fertility.

Authors:  Laura Fin; Giorgia Bergamin; Roberto A Steiner; Simon M Hughes
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

9.  Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist.

Authors:  Ziyi Liu; Malliga R Iyer; Grzegorz Godlewski; Tony Jourdan; Jie Liu; Nathan J Coffey; Charles N Zawatsky; Henry L Puhl; Jürgen Wess; Jaroslawna Meister; Jeih-San Liow; Robert B Innis; Sergio A Hassan; Yong Sok Lee; George Kunos; Resat Cinar
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-08

Review 10.  CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity.

Authors:  Arnau Busquets-Garcia; Jaideep Bains; Giovanni Marsicano
Journal:  Neuropsychopharmacology       Date:  2017-09-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.